These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
    Author: Konishi I, Kitani T, Nagai K, Kanamaru A, Kohsaki M, Masaoka T, Shibata H, Horiuchi A, Tsubaki K, Kawagoe H.
    Journal: Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122.
    Abstract:
    Twenty-five patients with malignant lymphomas were treated with etoposide oral capsule 200mg/day for 5 days, repeated 3-4-weekly. Twenty-one cases were evaluable. CR was achieved in four cases (19.0%) and PR in six cases (28.6%). The most serious adverse effect of the drug was leukopenia. In one patient (6.7%) the leukocyte count was lower than 1,000/mm3. Gastrointestinal toxicities such as anorexia, nausea, vomiting and diarrhea occurred in about 66.7% of patients but were not serious; alopecia was observed in 65.2%. In conclusion, etoposide is considered effective for malignant lymphomas.
    [Abstract] [Full Text] [Related] [New Search]